The Genomics of Opioid Addiction Longitudinal Study (GOALS): study design for a prospective evaluation of genetic and non-genetic factors for development of and recovery from opioid use disorder.
Addiction
Buprenorphine
Genetics
Medication for opioid use disorder (MOUD)
Opioid use disorder (OUD)
Substance misuse
Journal
BMC medical genomics
ISSN: 1755-8794
Titre abrégé: BMC Med Genomics
Pays: England
ID NLM: 101319628
Informations de publication
Date de publication:
07 01 2021
07 01 2021
Historique:
received:
23
11
2020
accepted:
25
11
2020
entrez:
8
1
2021
pubmed:
9
1
2021
medline:
26
11
2021
Statut:
epublish
Résumé
The opioid use disorder and overdose crisis in the United States affects public health as well as social and economic welfare. While several genetic and non-genetic risk factors for opioid use disorder have been identified, many of the genetic associations have not been independently replicated, and it is not well understood how these factors interact. This study is designed to evaluate relationships among these factors prospectively to develop future interventions to help prevent or treat opioid use disorder. The Genomics of Opioid Addiction Longitudinal Study (GOALS) is a prospective observational study assessing the interplay of genetic and non-genetic by collecting comprehensive genetic and non-genetic information on 400 participants receiving medication for opioid use disorder. Participants will be assessed at four time points over 1 year. A saliva sample will be collected for large-scale genetic data analyses. Non-genetic assessments include validated surveys measuring addiction severity, depression, anxiety, and adverse childhood experiences, as well as treatment outcomes such as urine toxicology results, visit frequency, and number of pre and post-treatment overdoses extracted from electronic medical records. We will use these complex data to investigate the relative contributions of genetic and non-genetic risk factors to opioid use disorder and related treatment outcomes.
Sections du résumé
BACKGROUND
The opioid use disorder and overdose crisis in the United States affects public health as well as social and economic welfare. While several genetic and non-genetic risk factors for opioid use disorder have been identified, many of the genetic associations have not been independently replicated, and it is not well understood how these factors interact. This study is designed to evaluate relationships among these factors prospectively to develop future interventions to help prevent or treat opioid use disorder.
METHODS
The Genomics of Opioid Addiction Longitudinal Study (GOALS) is a prospective observational study assessing the interplay of genetic and non-genetic by collecting comprehensive genetic and non-genetic information on 400 participants receiving medication for opioid use disorder. Participants will be assessed at four time points over 1 year. A saliva sample will be collected for large-scale genetic data analyses. Non-genetic assessments include validated surveys measuring addiction severity, depression, anxiety, and adverse childhood experiences, as well as treatment outcomes such as urine toxicology results, visit frequency, and number of pre and post-treatment overdoses extracted from electronic medical records.
DISCUSSION
We will use these complex data to investigate the relative contributions of genetic and non-genetic risk factors to opioid use disorder and related treatment outcomes.
Identifiants
pubmed: 33413350
doi: 10.1186/s12920-020-00837-3
pii: 10.1186/s12920-020-00837-3
pmc: PMC7792024
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
16Références
Arch Intern Med. 2006 May 22;166(10):1092-7
pubmed: 16717171
Curr Psychiatry Rep. 2014 Nov;16(11):504
pubmed: 25209027
Am J Psychiatry. 2003 Apr;160(4):687-95
pubmed: 12668357
Pain Med. 2005 Nov-Dec;6(6):432-42
pubmed: 16336480
J Pain. 2017 Sep;18(9):1046-1059
pubmed: 28456745
MMWR Morb Mortal Wkly Rep. 2016 Dec 30;65(50-51):1445-1452
pubmed: 28033313
Addict Behav. 2019 Nov;98:106056
pubmed: 31351326
Addict Behav. 2019 Jun;93:14-19
pubmed: 30682677
Mol Psychiatry. 2019 Dec;24(12):1868-1883
pubmed: 29934549
Curr Opin Psychol. 2019 Jun;27:31-35
pubmed: 30118972
J Addict Med. 2017 Jul/Aug;11(4):256-265
pubmed: 28590391
Natl Vital Stat Rep. 2016 Dec;65(10):1-15
pubmed: 27996932
Pain Med. 2008 May-Jun;9(4):444-59
pubmed: 18489635
Biol Psychiatry. 2020 Jan 1;87(1):82-88
pubmed: 31420089
Arch Gen Psychiatry. 1998 Nov;55(11):967-72
pubmed: 9819064
Biol Psychiatry. 2018 Nov 15;84(10):762-770
pubmed: 29478698
Behav Genet. 1999 Nov;29(6):473-9
pubmed: 10857252
Genes Brain Behav. 2018 Sep;17(7):e12476
pubmed: 29575474
J Clin Psychiatry. 2006 Feb;67(2):247-57
pubmed: 16566620
MMWR Morb Mortal Wkly Rep. 2020 Mar 20;69(11):290-297
pubmed: 32191688
J Subst Abuse Treat. 2012 Jul;43(1):114-22
pubmed: 22112506
Subst Use Misuse. 2014 Aug;49(10):1311-6
pubmed: 24708431
Curr Psychiatry Rev. 2014 May;10(2):156-167
pubmed: 25242908
Sci Rep. 2019 Mar 15;9(1):4660
pubmed: 30874594
Am J Med Genet. 1996 Sep 20;67(5):473-7
pubmed: 8886164
Mol Psychiatry. 2020 Aug;25(8):1673-1687
pubmed: 32099098
JAMA Psychiatry. 2014 Jul 1;71(7):821-6
pubmed: 24871348
J Subst Abuse Treat. 1992;9(3):199-213
pubmed: 1334156
Anesth Analg. 2017 Nov;125(5):1741-1748
pubmed: 29049118
Drug Alcohol Depend. 2006 Apr 28;82(2):135-42
pubmed: 16236466
Am J Public Health. 2018 Feb;108(2):182-186
pubmed: 29267060
Ann Emerg Med. 2019 Nov;74(5):634-646
pubmed: 31229388
Psychol Med. 2012 Jun;42(6):1261-72
pubmed: 21999943
J Gen Intern Med. 2001 Sep;16(9):606-13
pubmed: 11556941
Biol Psychiatry. 2014 Jul 1;76(1):66-74
pubmed: 24143882
Am J Prev Med. 2019 Jun;56(6):774-786
pubmed: 31104722
Mol Psychiatry. 2016 May;21(5):608-14
pubmed: 26239289